Announcements Trials
Browse Landscape

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 22Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

ESR1 Gene Mutation 1

Interventions

Blood Specimen Collection 121Surveys and Questionnaires 83Observation 50Radiotherapy 40Drug Therapy 35Surgical Procedures, Operative 34Biopsy 31Specimen Handling 28Data Collection 28Watchful Waiting 21Interviews as Topic 20Immune Checkpoint Inhibitors 19Magnetic Resonance Imaging 18Liquid Biopsy 16Immunotherapy 15Magnetic Resonance Spectroscopy 14Standard of Care 13pembrolizumab 12Tomography, X-Ray Computed 12Ultrasonography 11trastuzumab deruxtecan 10lenvatinib 10Radiosurgery 10Nivolumab 10Carboplatin 10Tissue Banks 9Restraint, Physical 9Radiation 9Neoadjuvant Therapy 9Endoscopy 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Observational × elacestrant × Clear all
NCT06544577 2024-08-09

Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

SciClone Pharmaceuticals

Recruiting
350 enrolled
Breast

ESR1 Gene Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡